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Abstract
Background: FLP recombinase mediated integration into a pre-integrated FRT site is routinely used to generate
highly reproducible stable transgenic cell lines. In this study, we broaden the system of site specific integration by
introducing FC31 integrase mediated integration into attP sites.
Results: We generated a HEK293 host cell line with a single copy FRT as well as an attP site allowing site specific
integration of two distinct transgenes. To achieve conditional control, we used the tetracycline and Shld1 inducible
systems. By introducing fluorescent reporters we show that integration and induction of two transgenes are
completely independent. We applied this new technique to investigate the effect of HNF4a on proliferation of
HEK293 cells by introducing HNF4a into each integration site. We obtained in two independent cell lines highly
reproducible results that prove the usefulness of this novel HEK-attP/FRT cell line.
Conclusions: In this study we have established and applied a HEK-attP/FRT cell line that allows site specific
integration of two conditional transgenes using the FLP recombinase as well as the FC31 integrase.
Background
Stable integration of inducible transgenes is widely used to
analyze gene function in mammalian cells. To obtain
highly reproducible results from different cell lines, site
specific integration of one single transgene copy is essen-
tial. Integration into a pre-determined genomic locus can
be achieved by FLP recombinase mediated integration [1]
and the tetracycline inducible expression system [2] is
most commonly used for conditional transgene activation.
The Flp-In T-REx™ system (Invitrogen) uses a genomic
FRT site for integration of any gene-of-interest (GOI) by
FLP recombinase and is based on the Tet-repressor (TetR)
that inhibits via two tetracycline operator (tetO) sequences
the CMV promoter of the GOI. This system has success-
fully been used to investigate factors that control cell pro-
liferation [3,4] and to reproducibly identify target genes of
transcription factors [5]. Recently, this system was further
improved by reducing the background expression of the
GOI, when no inducer is added [6].
For many experiments the independent conditional
expression of two distinct transgenes would be most
desirable. Thus, an additional and independent condi-
tional system is required. Recently, another inducible sys-
tem was developed that allows conditional protein
degradation [7]. The human FK506- and rapamycin-
binding protein (FKBP12) is rapidly and constitutively
degraded in mammalian cells. Protein fusion of its desta-
bilizing domain (DD) transfers the instability to any pro-
tein-of-interest. Addition of the synthetic ligand Shld1
that binds to the destabilizing domain protects the fusion
protein from rapid degradation and thus enhances abun-
dance of the protein-of-interest.
An enzyme that acts completely independent of FLP
and catalyses specific integration at high efficiency is the
serine integrase derived from the phage FC31. This
FC31 integrase mediates site-specific recombination
between two DNA sequences, the phage attachment site,
attP, and the bacterial attachment site, attB [8]. Impor-
tantly, recombining the attP and attB sites generates two
hybrid sites, attL and attR, which cannot be recognized
by the integrase and thus in contrast to the FLP recombi-
nase, the reaction is unidirectional and much more
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shown that a plasmid containing the attB sequences inte-
grates with different efficiency into pseudo attP sites of
the genomic DNA [9]. There are about 100 distinct inte-
grations sites that show different frequency of integration
[10]. Sequencing of these pseudo attP sites after integra-
tion showed that these recombinations were not comple-
tely precise at the sequence level, differing slightly at the
integration junction. In contrast the integration into
wild-type attP sites inserted into the mammalian genome
was invariable precise resulting in the expected recombi-
nation event at the sequence level. This property is most
valuable to design strategies to define attP site specific
integrations. Comparing in the human cell line HEK293
the integration frequency between the pseudo attP sites
and a wild-type attP site, about 15% of the integrations
occurred at the introduced wild-type attP site. In con-
trast, the most frequent pseudo attP site (phiA) was used
at 5% suggesting the wild-type attP site is preferred [9].
To prevent unwanted integration at pseudo attP sites a
selection is needed for specific integration at a pre-exist-
ing attP docking site using corresponding markers. This
can best be achieved by activation of an antibiotic resis-
tance gene upon proper recombination [9]. Significantly,
the fusion of a nuclear localization signal (NLS) to the
FC31 integrase has shown an eightfold increase in the
integrase activity [11] suggesting that this is an important
modification to get optimal activity in vertebrate cells.
In this study, we combine the Shld1 inducible system
with FC31 integrase mediated specific integration in the
background of the tetracycline inducible FLP mediated
system to have two completely independent ways of
transgene activation in one and the same cell. We apply
this technique to introduce the cell specific transcription
factor HNF4a into a human embryonic kidney
(HEK293) cell line and investigate its effect on cell
proliferation.
Results
Design of the integration systems
To allow site specific integration of two different trans-
genes we used two independent systems. The first is based
on FLP recombinase mediated recombination of FRT sites
(Figure 1A). By using hygromycin resistance, recombined
cell lines can be selected. Moreover, loss of lacZ reporter
activity monitors specific recombination with the FRT
integration vector. Conditional transcriptional control of
the transgene is achieved by applying the tetracycline
inducible system. This system is well established and com-
mercially available (Flp-In T-Rex™, Invitrogen). As a sec-
ond and independent system we developed FC31
integrase mediated recombination of attP and attB sites
(Figure 1B). To allow site directed integration of any gene-
of-interest (GOI) using the FC31 integrase, we designed
the docking construct pDOCKING-Neo containing the
attP recognition site. This site is linked in frame to an
ECFP-neomycin resistance fusion protein as selection
marker. As the attP site is placed downstream of the start
codon for ECFP-Neo, this marker will be inactivated upon
specific recombination with the corresponding attB
sequence. The incoming attB integration vector contains
the attB site fused to a promoter- and ATG-less puromy-
cin resistance gene, which is thus activated upon specific
recombination with the attP sequence of the docking site.
The GOI is placed downstream of the puromycin resis-
tance sequence. In all experiments we used the CMV pro-
moter and fused the GOI to the L106P mutant of the
human FKBP12 protein (destabilizing domain, DD) to reg-
ulate the expression on the level of protein stability by
Shld1 [7].
Generation of double docking HEK293 cell lines
T h ec o m m e r c i a l l ya v a i l a b l eF l p - I nT - R e x ™ HEK293
cells contain a stably integrated single copy FRT docking
site for FLP mediated integration. Using this cell line we
introduced in addition for FC31 mediated transgene
integration the newly generated attP docking site that
encodes an ECFP-Neo fusion gene. After selection with
G418 we selected 24 single clones with blue fluores-
cence. To determine the number of integrated transgene
copies we performed real-time PCR on genomic DNA
and selected the three double docking cell lines 12, 16,
and 19 with apparent single copy integration of the
docking site for further experiments.
Independent integration of inducible fluorescent proteins
into different double docking HEK293 cell lines
To test whether independent integration as well as inde-
pendent conditional activation of two different GOI can
be achieved in the double docking cell lines we generated
two different integration vectors. The FRT integration vec-
tor pcDNA5/FRT/TO-DsRed contains the red fluorescent
protein DsRed as GOI (Figure 1A), whereas the attP inte-
gration vector pINT-PuroDDEYFP contains as GOI the
yellow fluorescent protein EYFP linked to the destabilizing
domain (DD in Figure 1B). In a first round of transfection,
the DsRed gene was introduced using the FLP recombi-
nase. The obtained cell lines from each clone were used
for a second round of transfection using the EYFP con-
taining attP integration vector and the FC31 integrase.
The resulting cell lines were resistant to hygromycin and
puromycin and have thus potentially integrated the two
transgenes.
To test whether the two transgenes were present and
conditionally active, we treated all cell lines with doxycy-
cline, a relatively stable tetracycline derivative, or Shld1
and monitored red or yellow fluorescence (Figure 2). In
all cell lines derived from double docking cell lines 12,
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Page 2 of 10Figure 1 Scheme of the two independent integration systems used. A: FRT docking site is used as in the Flp-In T-Rex™ system (Invitrogen).
The FRT sequence is placed downstream and in frame of the translational initiation codon ATG from the lacZ-zeocin fusion protein. After FLP
mediated recombination with the FRT sequence of the integration vector, lacZ-zeocin expression is turned off and hygromycin resistance is
activated. The GOI (gene-of-interest) is placed downstream of the hygromycin resistance cassette and controlled by the tetracyclin inducible
CMV promoter containing the two tetracycline operators (2xtetO). B: attP docking site for FC31 integrase mediated integration. The attP
sequence is placed downstream and in frame of the translational initiation codon ATG from the ECFP-Neo fusion protein. After FC31 mediated
recombination with the attB sequence of the integration vector, ECFP-Neo expression is turned off and puromycin resistance is activated. The
GOI is placed downstream of the puromycin resistance cassette and controlled by the CMV promoter. The N-terminal destabilizing domain (DD)
is linked to the GOI to allow regulation by Shld1.
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Page 3 of 10Figure 2 Independent integration and induction of fluorescent reporters. Cells of the cell line 19-3-1 have the Shld1 inducible DD-EYFP
protein integrated into the attP docking site and the doxycycline inducible DsRed protein integrated into the FRT docking site. Cells were
cultured in six well plates and incubated with 1 μg/ml doxycycline or 1 μM Shld1 as indicated. After 24 h fluorescence was observed and
documented using a Leica MZ-FL III with appropriate filter sets as indicated.
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Page 4 of 1016, and 19, red fluorescence was specifically induced by
doxycycline and yellow fluorescence by Shld1 in more
than 90% of the cells. As an example, a cell line derived
from double docking cell line 19 is shown in Figure 2.
Clearly, there was no cross-reaction between the two
conditional systems, and both genes can be induced in
parallel. Next, we quantified the level of induction by
western blot analyses. Doxycycline treatment caused an
about 50-fold increased DsRed expression in the cell
lines 16-1-3 (Figure 3A) and 12-1-1 (not shown), and
about 20-fold induction in 19-3-1 (figure 3B). When
Shld1 was given to the cells, the DD-EYFP protein was
induced about 30-fold in 16-1-3 (Figure 3A), 20-fold in
12-1-1 (not shown), and 20-fold in 19-3-1 (Figure 3B). Of
note, in the cell lines 16-1-3 (Figure 3A) and 12-1-1 (not
shown) the ECFP-Neo fusion protein was still expressed.
We assume that in these cell lines there is at least one
un-recombined copy of the attP docking site present,
although the transgene was integrated. In contrast, the
cell line 19-3-1 lacks ECFP-Neo expression arguing for
recombination at a unique attP docking site. Thus, the
cell line 19, we refer to as HEK-attP/FRT cell line, is best
suited to achieve stable integration of two distinct trans-
genes with independent conditional activation of each
transgene.
Independent integration of two inducible HNF4a proteins
To verify that this double conditional system can also be
used to express genes interfering with cell cycle progres-
sion we introduced the transcription factor HNF4a splice
variant 2. (HNF4a2) that has been shown to inhibit
HEK293 cell multiplication [3,4] into each docking site.
In a first round of transfection, the doxycycline inducible
HNF4a2 sequence was introduced into the FRT site of
the HEK-attP/FRT cells using the FLP recombinase. Site
specific integration was verified by negative lacZ staining
in three independent cell lines. One cell line 19-2 was
used for a second round of transfection to integrate
Shld1 inducible HNF4a2 into the attP docking site using
FC31 integrase. The resulting four cell lines (19-2-2, 19-
2-6, 19-2-4 and 19-2-5) were resistant to hygromycin and
puromycin and have thus potentially integrated the two
transgenes. To verify site specific integration into the
attP docking site we screened for loss of ECFP-Neo
expression, which is inactivated upon recombination
(compare Figure 1B). This loss of ECFP-Neo expression
was validated by a western blot using a monoclonal anti-
GFP antibody also detecting ECFP (Figure 4A). The par-
ent cell line 19-2 shows expression of the 61 kDa ECFP-
Neo fusion protein, whereas no expression was detectable
in the cell lines 19-2-2 and 19-2-6 arguing for specific
integration of the HNF4a transgene in these cells. In
contrast, the cell lines 19-2-4 and 19-2-5 expressed an
about 27 kDa protein recognized by the anti-GFP anti-
body. In these two later cell lines the attP docking site
was possibly rearranged by illegitimate recombination
resulting in a truncated ECFP-Neo protein. We then
tested by western blot analyses whether HNF4a could be
induced in these cell lines by doxycycline or Shld1. As
the doxycycline inducible HNF4a transgene contains a
Figure 3 Quantification of reporter activation by western blot. Lysates of cell line 16-1-3 (A) or 19-3-1 (B) were probed by western blots
using an anti-DsRed antibody (left panels) or an anti-GFP antibody (right panels). Cell lysates were diluted as indicated. Note that the GFP
antibody recognizes EYFP as well as ECFP. 1 μg/ml doxycycline or 1 μM Shld1 was added as indicated.
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and Shld1 inducible proteins. In all four cell lines the
myc-tagged HNF4a transgene could be induced specifi-
cally by doxycycline to a most similar level (Figure 4B,
lower panel). However, when treated with Shld1 the cell
lines 19-2-2 and 19-2-6 showed activation of HNF4a,
whereas the cell lines 19-2-4 and 19-2-5 lacked HNF4a
expression despite of puromycin resistance indicating
FC31 mediated integration of the transgene. The ability
to induce HNF4a by Shld1 in the cell lines 19-2-2 and
19-2-4 correlates with the loss of ECFP-Neo expression
indicating specific integration in these two cell lines. In
contrast, the cell lines 19-2-4 and 19-2-5 still expressing
a truncated ECFP-Neo protein were not inducible by
Shld1.
To address the effect of both HNF4a transgenes on cell
cycle progression we treated the cell lines 19-2-2 and 19-
2-6 with doxycycline and/or Shld1 and measured the cell
number over five days by the MTS assay. The cell line
19-2-2 showed an about 10-fold increase of cell mass
until day 5 (Figure 5A). However, when doxycycline or
Shld1 was given cell multiplication was significantly
r e d u c e db y5 - f o l do r6 - f o l d ,r e s p e c t i v e l y .S i g n i f i c a n t l y ,
administration of doxycycline and Shld1 in parallel
retained the cell number at about the starting levels
pointing to an additive effect of the two independent
HNF4a transgenes. MTS assay of the 19-2-6 cell line
(Figure 5B) showed most similar results with a significant
reduction of cell multiplication by either doxycycline or
Shld1 treatment and a lack of cell multiplication, if doxy-
cyline and Shld1 were applied simultaneously.
In summary, the two HNF4a transgenes could be
independently activated by doxycycline or Shld1 and the
observed effect on cell multiplication was highly
Figure 4 Independent integration of two inducible HNF4a proteins. A: Western blot analysis was performed on the 19-2 parent cell line
containing the myc tagged HNF4a2 coding region in the FRT site and on the four FC31 mediated descendent cell lines 19-2-2, 19-2-6, 19-2-4,
and 19-2-5. The anti-GFP antibody recognizes ECFP. B: Western blot analysis of the cell lines 19-2-2, 19-2-6, 19-2-4, and 19-2-5 using an anti-
HNF4a or anti-myc antibody. The cells were cultured in six well plates, incubated with 1 μg/ml doxycycline and/or 1 μM Shld1 as indicated and
protein extracts prepared after 24 h. As the HNF4a transgene introduced into the FRT docking site has a myc-tag, it can be detected specifically
with the anti-myc antibody. The anti-HNF4a antibody detects the myc-tagged as well as the DD-tagged HNF4a proteins that differ slightly in
size (compare e.g. lanes 2 and 3).
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Page 6 of 10Figure 5 Effect of HNF4a on cell proliferation. MTS proliferation assay was performed over a time span of five days in cell line 19-2-2 (A)o r
cell line 19-2-6 (B). Cells were treated with 1 μg/ml doxycycline and/or 1 μM Shld1 at day 0 as indicated and the metabolic activity was
determined at the given time points. The medium was not changed during the whole period. The assay was performed in 96 well plates with n
= 3 measurements. Using the student’s t-test p-values were calculated for doxycycline or Shld1 treatment compared to control: *p < 0.01.
Similarly, p-values comparing double treated samples (doxycycline and Shld1) with doxycycline treated samples were computed:
+p < 0.01. The
results were confirmed in an additional independent experiment for each cell line. We did not observe any effects of doxycycline or Shld1 on
cell proliferation of HEK293 cells without the HNF4a transgene.
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Page 7 of 10reproducible between the two distinct sites of integra-
tion in two individual cell lines. Moreover, the effect of
HNF4a appears to be concentration dependent, as acti-
vation of the second transgene further delays cell
multiplication.
Discussion
In this study we created the double conditional cell line
HEK-attP/FRT to independently control the expression
of two stably integrated transgenes. While stable cell
lines are superior to transient transfectants to investigate
long term effects, there is considerable variation between
different clones as the site of integration and number of
transgene copies cannot be predicted using standard
transfection methods. This variation becomes even more
problematic, when two potentially interacting transgenes
are studied. This problem has now been overcome by
using in parallel FLP and FC31 integrase mediated inte-
gration into the corresponding pre-integrated recognition
sites.
When searching for the optimal HEK-attP/FRT docking
cell line, it turned out that two of three host cell lines still
expressed the marker for the native attP docking site after
integration of the fluorescent proteins. As the cells were
resistant to puromycin and the fluorescent proteins could
be properly induced, we conclude that there is least one
additional un-recombined copy of the attP docking site
present in these cells. However, the finally selected HEK-
attP/FRT cell line appears useful for single copy integra-
tion, as it allows recombination at a unique site resulting
in loss of the attP marker gene expression (19-3-1 in
Figure 3A). All experiments confirm that induction by
doxycycline or Shld1 is completely independent (Figure 2,
3 and 4). This could be expected, as gene activation by
doxycycline (or tetracycline, tet-On system) acts on
the transcriptional level [2], while Shld1 affects protein sta-
bility [7]. To have both, transcriptional and post-transla-
tional control, in one cell makes this system most
versatile. The fold induction was comparable between the
two systems (Figure 4B), although we cannot exclude that
the myc tagged HNF4a protein and the DD-HNF4a
fusion protein, in the presence of Shld1, have distinct sta-
bilities. While in theory FC31 integrates more efficiently
than FLP [8], we did not obtain more clones by FC31
mediated integration than by FLP in our experiments.
Integrating HNF4a into the HEK-attP/FRT cell line it
appeared necessary to screen for correct integration by
loss of ECFP-Neo expression (Figure 4). Illegitimate
recombination or integration at pseudo attP sites can
probably not completely be avoided by puromycin selec-
tion, but the loss of ECFP-Neo expression (cell lines 19-
2-2 and 19-2-6) correlated perfectly with proper Shld1
inducibility in these two cell lines. The occurrence of
unspecific integration was comparable to unspecific
recombination events observed using FLP mediated inte-
gration that results in a high proportion of lacZ positive
cells (own observations). The fact that doxycycline or
Shld1 induced HNF4a has nearly the same quantitative
effect on cell proliferation in two independent cell lines
(Figure 5) implies that the two distinct HNF4a fusion
proteins integrated at two distinct loci have most similar
physiological properties. Of note, there was also an addi-
tive effect, if the two copies were activated simulta-
neously. This underlines the usefulness of the double
conditional cell line HEK-attP/FRT to study the function
of two potentially synergistic factors. Future applications
for this novel cell line will also include the introduction
of two different proteins with opposing functions allow-
ing the study of any induced downstream signaling.
Recently, another technique to introduce two different
transgenes into two distinct sites was established using
recombinase mediated cassette exchanged (RMCE) [12],
but no conditional control of transgene expression was
applied. While the system of multiplexing RMCE has the
advantage of introducing two transgenes in one step, no
specific selection markers for integration into each site
were used. The integration of the transgenes in two
stages as in our system is time consuming. One possibi-
lity to speed up this process could be to transfect the
host cells in parallel with FLP and FC31 integrase and
the corresponding integration vectors in a single trans-
fection. However, we did not test this ambitious option.
During preparation of our manuscript a multi-integrase
system involving even five distinct recombination sites
has been described [13]. However, our system allows in
addition the conditional expression of two independent
genes integrated at well defined genomic positions.
Conclusions
In this study we have established and applied a HEK-attP/
FRT cell line that allows site specific integration of two
distinct transgenes using the FLP recombinase as well as
the FC31 integrase. Moreover, this approach implicates
two specific conditional systems to control transgene
expression.
Methods
Cell culture and transfection
All cell lines were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco-BRL) supplemented with 10%
heat inactivated fetal calf serum (FCS), penicillin/strepto-
mycin (100 U/ml) and 2 mM glutamine at 37°C under 8%
CO2 atmosphere and a relative humidity of 95%. The cell
line Flp-In T-Rex™ 293 (Invitrogen) was cultured in
DMEM supplemented with 15 μg/ml blasticidin and
100 μg/ml zeocin (InvivoGen). The HEK-attP/FRT cell
line was kept in DMEM supplemented with blasticidin,
zeocin, and 500 μg/ml G418 (InvivoGen). To select stable
Waldner et al. BMC Research Notes 2011, 4:420
http://www.biomedcentral.com/1756-0500/4/420
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integration into the FRT docking site, zeocin was substi-
tuted with 50 μg/ml hygromycin B (Invitrogen). After
FC31 integrase mediated integration into the attP docking
site, G418 was replaced by 1 μg/ml puromycin (Invivo-
Gen). Transfections were carried out using LipofectA-
MINE™ (Invitrogen) or FuGENE™ (Roche).
Generation and induction of stable cell lines
For integration into the FRT docking site, cells were co-
transfected with the FLP expression vector pCSFLPe [14]
and the corresponding integration vector at a ratio of 9 to
1. As the transgenes are integrated at the same chromoso-
mal site, cell lines were prepared by pooling individual
colonies. Successful integration was verified by staining
the cells for b-galactosidase activity. Cell lines with less
than 5% blue cells were used for further experiments. For
integration into the attP docking site, cells were co-trans-
fected with the FC31 integrase expression vector
pchactC31hum (Artemis) and the corresponding integra-
tion vector at a ratio of 9 to 1. For conditional expression
of transgenes, cells were cultured in 1 μg/ml doxycycline
or 1 μM Shld1. In all experiments, cells were seeded 24 h
before induction. To measure the cell proliferation rate,
MTS assay was performed according to the manufacturer’s
instructions (CellTiter 96R Aqueous One Solution Cell
Proliferation Assay, Promega).
Real-time PCR
DNA was extracted using the DNeasy Extraction Kit (Qia-
gen). Real time PCR was performed using POWR-SYBR
Green (Applied Biosystems) on a 7900HT Sequence
Detection System (Applied Biosystems). Templates of 10
ng DNA were measured in duplicate. The number of
transgene copies was determined by external calibration
using the b-actin gene for normalization. Primers used
were docking1: 5’-GCAAAGACCCCAACGAGAAG-3’,
docking2: 5’-TCACGAACTCCAGCAGGACC-3’,h A C
TBf: 5’-GGTATCTCCCTCTGCAGC-3’,h A C T B r :5 ’-
CTATGGGCTGAGGTCTGGAT-3’.
Western blot analysis
Cell pellets were lysed in RIPA buffer (50 mM Tris-HCl
pH 7.2, 150 mM NaCl, 0.1% sodium dodecylsulfate, 1%
sodium deoxycholate, 1% Triton X-100) supplemented
with 0.2% protease inhibitor cocktail (Sigma, P-8340).
Insoluble debris were removed by centrifugation at 14,000
g for 10 min at 4°C. The protein concentration of the
supernatant was determined using a Bradford assay (Bio-
Rad). Equal amounts of proteins were separated on SDS-
polyacrylamide gels and transferred to nitrocellulose.
Membranes were blocked with blocking reagent (Amer-
sham, RPN 3601). For antigen detection, monoclonal anti-
myc tag antibody 9E10, anti-HNF4a (Santa Cruz, C-19),
anti-GFP (Clonetech, JL-8 632380), anti-DsRed (Clone-
tech, 632496) antibodies were employed. Peroxidase-con-
jugated anti-mouse IgG (Amersham), anti-rabbit IgG
(Jackson ImmunoResearch) and anti-goat IgG (Sigma)
were used as secondary antibodies. Immunoreactivity was
detected by ECL (Amersham Biosciences).
Plasmids
pDOCKING-Neo (Addgene plasmid 31441) contains the
CMV promoter driven ECFP-neomycin fusion protein
containing the blue fluorescent protein ECFP (Clone-
tech). A minimal attP site [15] is placed downstream and
in frame of its start codon. In addition, a loxP site was
integrated upstream of the start codon. The attB integra-
tion vector pINT-PuroDDEYFP (Addgene plasmid
31442) contains a minimal attB site [15] fused in frame
to an ATG-less puromycin resistance gene. Downstream
of this sequence there is as GOI a CMV promoter driven
DD-EYFP fusion protein with the L106P mutant of the
human FKBP12 protein (destabilizing domain) [7] linked
in frame with the yellow fluorescent protein EYFP
(Clonetech). The attB integration vector pINT-Pur-
oDDHNF4a2 (Addgene plasmid 31443) contains as GOI
a CMV promoter driven DD-HNF4a2 fusion protein. In
the FRT integration vector pcDNA5/FRT/TO-DsRed the
DsRed sequence (Clonetech) was introduced into the
multiple cloning site of the pcDNA5/FRT/TO vector
(Invitrogen) to obtain FR_DsRed2 (Addgene plasmid
31444). The FRT integration vector pcDNA5/FRT/TO-
HNF4a2 has been described [3]. All constructs were
made using standard molecular procedures. The com-
plete sequence information of all plasmids used can be
obtained on request.
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